tiprankstipranks
Trending News
More News >
Zentek (TSE:ZEN)
:ZEN

Zentek (ZEN) AI Stock Analysis

Compare
69 Followers

Top Page

TSE:ZEN

Zentek

(ZEN)

Select Model
Select Model
Select Model
Neutral 40 (OpenAI - 4o)
Rating:40Neutral
Price Target:
C$0.97
▼(-4.90% Downside)
Zentek's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, with the stock trading below key moving averages. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively suggest significant challenges for the company.
Positive Factors
Business Model Strength
The focus on graphene-based technologies positions Zentek in a niche market with potential for high growth, leveraging innovative solutions in healthcare and energy.
Partnerships and Collaborations
Strategic partnerships enhance Zentek's market reach and innovation capability, providing a platform for sustainable growth through collaborative development.
Government Support
Government grants provide financial support and validation for Zentek's R&D efforts, reducing financial strain and fostering innovation in advanced materials.
Negative Factors
Declining Revenue
Declining revenue indicates challenges in market demand or competitive positioning, which can hinder long-term growth and profitability.
Cash Flow Challenges
Negative cash flow impacts Zentek's ability to fund operations and invest in growth initiatives, threatening financial stability and operational flexibility.
Profitability Issues
Persistent losses and negative margins indicate operational inefficiencies and market challenges, undermining Zentek's ability to achieve sustainable profitability.

Zentek (ZEN) vs. iShares MSCI Canada ETF (EWC)

Zentek Business Overview & Revenue Model

Company DescriptionZentek Ltd. (ZEN) is a Canadian technology company specializing in advanced materials and innovative solutions for various industries, including healthcare, energy, and environmental sectors. The company is focused on developing and commercializing its proprietary graphene-based technologies, which are designed to enhance the performance and efficiency of products in fields such as air filtration, antimicrobial coatings, and energy storage.
How the Company Makes MoneyZentek generates revenue primarily through the commercialization of its graphene-based products and technologies. The company has established key partnerships with industry players and research institutions to develop and market its innovative solutions. Revenue streams include sales of its air filtration systems, licensing agreements for its intellectual property, and collaborative research contracts. Additionally, Zentek benefits from government grants and funding aimed at supporting innovative technological advancements, which further contribute to its earnings.

Zentek Financial Statement Overview

Summary
Zentek is facing considerable financial difficulties with declining revenues and persistent losses. The balance sheet shows low leverage but poor profitability, and cash flow challenges are significant with negative operating cash flows and declining free cash flow.
Income Statement
30
Negative
Zentek's income statement reveals significant challenges. The company has experienced negative revenue growth in the TTM, indicating a decline in sales. Profitability metrics such as net profit margin and EBIT margin are deeply negative, reflecting substantial losses. Despite a slight improvement in gross profit margin, the overall financial health remains weak due to persistent negative earnings.
Balance Sheet
45
Neutral
The balance sheet shows moderate leverage with a low debt-to-equity ratio, which is a positive sign of financial stability. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is relatively stable, suggesting a decent proportion of equity financing, but the negative ROE highlights ongoing profitability issues.
Cash Flow
35
Negative
Zentek's cash flow statement highlights significant cash flow challenges. The operating cash flow to net income ratio is negative, indicating cash outflows from operations. Free cash flow growth is negative in the TTM, suggesting deteriorating cash generation. Although the free cash flow to net income ratio is slightly above 1, it is primarily due to negative net income, not improved cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue915.32K872.50K29.82K72.86K339.67K2.35K
Gross Profit452.53K192.49K-385.06K-780.48K-275.04K-124.44K
EBITDA-7.64M-9.35M-11.08M-13.75M-11.27M-3.73M
Net Income-8.19M-10.04M-11.70M-14.41M-38.69M-3.87M
Balance Sheet
Total Assets16.87M18.40M22.59M33.29M37.98M30.25M
Cash, Cash Equivalents and Short-Term Investments1.33M121.48K3.52M10.36M26.68M3.09M
Total Debt1.89M680.47K1.24M1.61M2.23M404.32K
Total Liabilities5.18M3.65M2.41M2.90M3.44M2.79M
Stockholders Equity11.69M14.75M20.17M30.38M34.55M27.46M
Cash Flow
Free Cash Flow-5.80M-6.28M-8.37M-15.23M-11.97M-2.05M
Operating Cash Flow-5.42M-6.28M-8.05M-12.96M-7.99M-1.79M
Investing Cash Flow2.40M358.65K1.88M-2.31M-7.25M-1.23M
Financing Cash Flow1.42M2.52M-665.47K-1.05M38.82M5.31M

Zentek Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.02
Price Trends
50DMA
1.08
Negative
100DMA
1.11
Negative
200DMA
1.41
Negative
Market Momentum
MACD
-0.03
Negative
RSI
46.22
Neutral
STOCH
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZEN, the sentiment is Negative. The current price of 1.02 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.08, and below the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZEN.

Zentek Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
C$213.09M-13.96-10.51%2.48%-53.76%
58
Neutral
C$48.34M-29.63-21.89%26.36%
58
Neutral
C$88.83M129.170.87%2.14%-83.06%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
40
Neutral
C$107.31M-12.74-52.95%2225.73%25.94%
40
Underperform
C$54.81M-16.90-2846.90%10.97%
26
Underperform
C$80.65M-32.9710.49%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:ZEN
Zentek
1.00
-0.41
-29.08%
TSE:ARCH
Arch Biopartners
1.22
-0.61
-33.33%
TSE:BUX
BioMark Diagnostics
0.48
0.28
140.00%
TSE:MDP
Medexus Pharmaceuticals Inc
2.79
-0.51
-15.45%
TSE:QIPT
Quipt Home Medical
4.82
1.06
28.19%
TSE:SONA
Sona Nanotech Inc
0.48
0.24
100.00%

Zentek Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Zentek Appoints Mohammed Jiwan as CEO to Drive Growth
Positive
Nov 25, 2025

Zentek Ltd. has appointed Mohammed Jiwan as the new Chief Executive Officer, effective December 1, 2025. Jiwan brings over 20 years of experience in operational and capital markets leadership, particularly in technology, healthcare, and life sciences. His appointment is seen as a strategic move to guide Zentek into its next phase of growth, focusing on unlocking the full value of its technologies and assets. The company also announced the granting of stock options and restricted share units to certain officers, directors, and consultants, indicating a commitment to aligning leadership incentives with shareholder value creation.

Legal ProceedingsRegulatory Filings and Compliance
Zentek Faces CRA Reassessment on 2019 Flow-Through Financings
Negative
Nov 21, 2025

Zentek Ltd. has received a notice of reassessment from the Canada Revenue Agency (CRA) concerning its 2019 financial year, related to its flow-through financings. The CRA has reclassified approximately $199,000 of Canadian exploration expenses, resulting in a tax assessment of $22,481.89. Zentek is required to indemnify subscribers affected by the reassessment, with a maximum liability of $427,000. This reassessment may impact Zentek’s financial obligations and its relationship with investors involved in the flow-through financings.

Product-Related AnnouncementsBusiness Operations and Strategy
Zentek Unveils Innovative Fire-Retardant Product with Exclusive US Licensing
Positive
Nov 5, 2025

Zentek Ltd. has developed a new Graphite Gel-Based Fire-Retardant product designed to protect homes from wildfires. The product, which combines rapid gelation and intumescent components, has been licensed exclusively to Altek Advanced Materials Inc. for commercialization in the US under the name GraphGel™. The coating has been tested to achieve a Class A fire rating and can be rapidly applied to structures, offering significant protection. This development addresses the growing need for effective fire management solutions amid increasing wildfire incidents.

Private Placements and FinancingBusiness Operations and Strategy
Zentek Closes $2.48M Private Placement to Strengthen Operations
Positive
Oct 22, 2025

Zentek Ltd. has successfully closed a non-brokered private placement of units, raising gross proceeds of $2,479,227. The funds will be allocated for general and administrative corporate purposes. This financial move is expected to bolster the company’s operational capabilities and potentially enhance its market positioning. The offering included common shares and warrants, with certain directors participating, marking it as a related party transaction under regulatory guidelines.

Private Placements and Financing
Zentek Upsizes Private Placement to $2.5 Million
Neutral
Oct 20, 2025

Zentek Ltd. has announced an increase in its non-brokered private placement to raise up to $2,500,000, with each unit priced at $1.06. The proceeds will be used for working capital and general corporate purposes. Each unit comprises one common share and two half-warrants, which can be converted into common shares at specified prices and conditions. The offering is subject to regulatory approvals and includes a hold period for the issued securities.

Product-Related AnnouncementsBusiness Operations and Strategy
Zentek’s Albany Graphite Achieves Key Milestones in Nuclear Suitability Testing
Positive
Oct 6, 2025

Zentek’s subsidiary, Albany Graphite Corp., announced successful results from nuclear suitability testing of its ultra-high purity graphite, confirming its potential use in the nuclear energy industry. The tests demonstrated that Albany graphite meets or exceeds nuclear-grade requirements in areas such as particle size distribution, compressibility, resistivity, and friction, highlighting its reliability and safety for demanding nuclear applications.

Private Placements and FinancingBusiness Operations and Strategy
Zentek Announces $2 Million Private Placement to Support Growth
Positive
Oct 1, 2025

Zentek Ltd. has announced a non-brokered private placement aiming to raise up to $2,000,000 through the issuance of units priced at $1.06 each. The proceeds will be used for working capital and general corporate purposes. Each unit includes common shares and purchase warrants, with specific terms for Series A and Series B warrants. This move is part of Zentek’s strategy to bolster its financial resources and support its ongoing operations and development projects. Additionally, the company has granted stock options and restricted share units to its officers, directors, and employees, further aligning their interests with the company’s growth objectives.

Executive/Board ChangesShareholder Meetings
Zentek Announces Successful Shareholder Meeting and Leadership Transition
Positive
Sep 25, 2025

Zentek Ltd. announced the successful voting results from its annual and special meeting of shareholders, where all resolutions were approved, including the election of board members and the appointment of BDO Canada LLP as auditors. Notably, John Snisarenko was appointed as the new Chair of the Board, succeeding Eric Wallman. This leadership change is seen as a strategic move to support Zentek’s growth ambitions and enhance shareholder value as the company transitions its CEO and continues to develop its innovative technologies.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Zentek Announces Leadership Change and Advances Air Filter Innovation
Positive
Sep 24, 2025

Zentek Ltd. announced a leadership transition with CFO Wendy Ford stepping in as Interim CEO following the resignation of former CEO Greg Fenton. The company is actively searching for a new CEO to guide its next growth phase. Zentek’s ZenGUARD™ Enhanced Air Filters have demonstrated superior performance in removing infectious aerosols, aligning with ASHRAE standards, and are being positioned for widespread adoption in Canada through government procurement and partnerships. This strategic move aims to enhance market penetration and accelerate revenue growth, particularly in sectors like healthcare and education.

Product-Related AnnouncementsBusiness Operations and Strategy
Zentek’s Albany Graphite Achieves Ultra-High Purity for Nuclear Applications
Positive
Sep 22, 2025

Zentek’s subsidiary, Albany Graphite Corp., has achieved a significant milestone by purifying Albany graphite to an ultra-high 5N purity level, making it suitable for nuclear applications. This development positions Albany graphite as a rare natural alternative to synthetic graphite, with potential implications for the nuclear energy sector, especially as countries like Canada and the U.S. expand their nuclear energy capacities. The purification process, which avoids halogen gases, offers a cost-effective and environmentally friendly solution, enhancing the material’s appeal for high-growth markets.

Product-Related AnnouncementsBusiness Operations and Strategy
Zentek’s Influenza Countermeasure Shows Promising Results in Preliminary Tests
Positive
Sep 18, 2025

Zentek Ltd. has successfully completed the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1) using multivalent aptamer technology. The testing, part of the Innovative Solutions Canada Testing Stream, showed promising results, with treated animals exhibiting improved clinical scores and higher survival rates compared to the control group. This development, supported by a $1.1 million award from the Government of Canada, marks a significant step in Zentek’s efforts to address both seasonal and potentially pandemic influenza strains, positioning the company as a key player in the advanced medical technologies sector.

Executive/Board ChangesShareholder Meetings
Zentek Updates Board Nominees with New Expertise
Positive
Sep 10, 2025

Zentek Ltd. has announced an updated slate of independent director nominees for its upcoming annual general and special meeting. The new nominees include Matt Fontes and Pete Gettinby, who bring expertise in building innovation and renewable energy, respectively. This strategic update aims to enhance Zentek’s board with diverse skills and experiences, potentially strengthening its market position and operational capabilities.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025